Medical Policy Revision: Recombinant Interleukin-2 (IL-2)
Effective June 15, 2016, Horizon Blue Cross Blue Shield of New Jersey will change the way we consider certain claims for recombinant interleukin-2 (IL-2).
According to the guidelines of our medical policy, Recombinant Interleukin-2 (IL-2), recombinant interleukin-2 (IL-2) may be considered an investigational service for certain on- and off-label uses.
We encourage you to review this policy in our online Medical Policy Manual.
Based on the guidelines of our Recombinant Interleukin-2 (IL-2) medical policy and the submitted diagnosis code(s):
- HCPCS code J9015 included on claims for services provided on and after June 15, 2016 to a member enrolled in any Horizon BCBSNJ plan (including members enrolled in Horizon BCBSNJ Medicare Advantage plans) will be denied as an investigational service.
Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been cancelled or postponed, the changes will be applied to claims for dates of service on and after June 15, 2016.